Chronic PeriodontitisNCT07538661
Metabolic Regeneration Registry for Periodontal Health (20-Patient Cohort).
An observational study of Chronic Periodontitis and Chronic Periodontitis Wth Diabetes Mellitus, run by Amar h Zireg at 1 site in Algeria.
Trial summary
This observational study documents the clinical outcomes of a proprietary, safe-to-swallow metabolic protocol for chronic gum disease. Based on 21 years of research and a focused 20-patient cohort, the study records visible clinical improvements in gingival inflammation and tissue color within 7 to 14 days. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Periodontitis, Chronic Periodontitis Wth Diabetes Mellitus, Non-surgical Periodontal Treatment
- What is being tested?
- Nutraceutical Bio-Active Oral Repair Formula (Food-Grade) and Nutraceutical Bio-Active Oral Repair Formula
- Type of treatment
- Pill or oral medicine
- How many people
- 20 participants
- Where
- 1 siteAlgeria
- Study dates
- 3 Jan 2026to 26 Feb 2026
- How long will I take part?
- 30 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients aged 18 to 75 years diagnosed with chronic periodontitis, characterized by gingival inflammation, bleeding on probing, and periodontal pocket depths of 4mm or greater. The population includes individuals seeking non-surgical alternatives for gum tissue recovery.
Who may be able to join
- Patients (18-75) with documented chronic periodontitis and pocket depths >4mm.
Who cannot join
- Active oral malignancy or pregnancy
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Retrospective Longitudinal Observation of a Proprietary Metabolic Protocol for Rapid Gingival Tissue Repair and Periodontal Pocket Stabilization.
This observational study documents the clinical outcomes of a proprietary, safe-to-swallow metabolic protocol for chronic gum disease. Based on 21 years of research and a focused 20-patient cohort, the study records visible clinical improvements in gingival inflammation and tissue color within 7 to 14 days. The protocol focuses on restoring the metabolic environment to achieve non-surgical periodontal pocket stabilization and natural tissue re-attachment.
- Conditions
- Chronic Periodontitis, Chronic Periodontitis Wth Diabetes Mellitus, Non-surgical Periodontal Treatment, Gingival Regeneration, Metabolic Repair
- Being tested
- Nutraceutical Bio-Active Oral Repair Formula (Food-Grade), Nutraceutical Bio-Active Oral Repair Formula
- Keywords
- Gingival Regeneration, Metabolic Repair, Non-Surgical Periodontal Treatment
- Medical subject headings
- Chronic Periodontitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nutraceutical Bio-Active Oral Repair Formula (Food-Grade)Dietary supplement
Topical application of a proprietary, 100% food-grade (GRAS) nutraceutical formulation specifically designed for rapid gingival tissue regeneration and inflammation reversal.
Key Performance Indicators:
Speed: Clinical onset of action visible within 3 days. Safety: Completely safe for ingestion (edible), eliminating common side effects of chemical antiseptics like staining or taste alteration.
Efficacy: Significant reduction in redness and bleeding (BOP) within 7 to 14 days, as demonstrated in our cohort of 20+ subjects.
Mechanism: Supports the natural healing of the gum 'peau' (epithelium) through host-response modulation rather than harsh disinfection.
Nutraceutical Bio-Active Oral Repair FormulaDietary supplement
Topical application of a proprietary, 100% food-grade (GRAS) nutraceutical formulation specifically designed for rapid gingival tissue regeneration and inflammation reversal.Key Performance Indicators:
Speed: Clinical onset of action visible within 3 days. Safety: Completely safe for ingestion (edible), eliminating common side effects of chemical antiseptics like staining or taste alteration.
Efficacy: Significant reduction in redness and bleeding (BOP) within 7 to 14 days, as demonstrated in our cohort of 20+ subjects.
Mechanism: Supports the natural healing of the gum 'peau' (epithelium) through host-response modulation rather than harsh disinfection."
What is being measured
The primary outcome is the main question the study is designed to answer.
Visible reduction in gingival inflammation and erythema (redness) observed within 7 to 14 days
Measured: 7 to 14 days
Secondary outcomes (1)
Measurement of periodontal pocket depth reduction and tissue stability at 6 weeks
Measured: 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Apr 2026
- Study start3 Jan 2026
- Primary completion20 Feb 2026
- Study completion26 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic PeriodontitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20 participants (actual)
- Target duration
- 30 Days
Sponsor and investigators
- Lead sponsor
- Amar h Zireg
- Sponsor type
- University, hospital or other
- Collaborators
- Self funded
- Responsible party
- Sponsor-investigator, Amar h Zireg, Amar Zireg
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07538661
- Sponsor's protocol ID
- ZIREG-ORAL-2026
- Status last verified
- Apr 2026
- First submitted
- 13 Apr 2026
- Last updated
- 28 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Retrospective Longitudinal Observation of a Proprietary Metabolic Protocol for Rapid Gingival Tissue Repair and Periodontal Pocket Stabilization.
- ClinicalTrials.gov ID
- NCT07538661
- Acronym / sponsor ID
- ZIREG-ORAL-2026
- Conditions
- Chronic Periodontitis, Chronic Periodontitis Wth Diabetes Mellitus, Non-surgical Periodontal Treatment, Gingival Regeneration, Metabolic Repair
- Keywords
- Gingival Regeneration, Metabolic Repair, Non-Surgical Periodontal Treatment
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Amar h ZiregUniversity, hospital or other
- Collaborators
- Self funded
- Study start
- 3 Jan 2026 (actual)
- Primary completion
- 20 Feb 2026 (actual)
- Study completion
- 26 Feb 2026 (actual)
- First posted
- 20 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This observational study documents the clinical outcomes of a proprietary, safe-to-swallow metabolic protocol for chronic gum disease. Based on 21 years of research and a focused 20-patient cohort, the study records visible clinical improvements in gingival inflammation and tissue color within 7 to 14 days. The protocol focuses on restoring the metabolic environment to achieve non-surgical periodontal pocket stabilization and natural tissue re-attachment.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 30 Days
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients aged 18 to 75 years diagnosed with chronic periodontitis, characterized by gingival inflammation, bleeding on probing, and periodontal pocket depths of 4mm or greater. The population includes individuals seeking non-surgical alternatives for gum tissue recovery.
Key inclusion criteria (1 listed)
- Patients (18-75) with documented chronic periodontitis and pocket depths >4mm.
Key exclusion criteria (1 listed)
- Active oral malignancy or pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nutraceutical Bio-Active Oral Repair Formula (Food-Grade)Topical application of a proprietary, 100% food-grade (GRAS) nutraceutical formulation specifically designed for rapid gingival tissue regeneration and inflammation reversal. Key Performance Indicators: Speed: Clinical onset of action visible within 3 days. Safety: Completely safe for ingestion (edible), eliminating common side effects of chemical antiseptics like staining or taste alteration. Efficacy: Significant reduction in redness and bleeding (BOP) within 7 to 14 days, as demonstrated in our cohort of 20+ subjects. Mechanism: Supports the natural healing of the gum 'peau' (epithelium) through host-response modulation rather than harsh disinfection. | Dietary supplement | – |
| Nutraceutical Bio-Active Oral Repair FormulaTopical application of a proprietary, 100% food-grade (GRAS) nutraceutical formulation specifically designed for rapid gingival tissue regeneration and inflammation reversal.Key Performance Indicators: Speed: Clinical onset of action visible within 3 days. Safety: Completely safe for ingestion (edible), eliminating common side effects of chemical antiseptics like staining or taste alteration. Efficacy: Significant reduction in redness and bleeding (BOP) within 7 to 14 days, as demonstrated in our cohort of 20+ subjects. Mechanism: Supports the natural healing of the gum 'peau' (epithelium) through host-response modulation rather than harsh disinfection." | Dietary supplement | – |
Primary outcome
Visible reduction in gingival inflammation and erythema (redness) observed within 7 to 14 days
Time frame: 7 to 14 days
1 secondary outcome
Measurement of periodontal pocket depth reduction and tissue stability at 6 weeks
Time frame: 6 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Apr 2026.
Related trials for Chronic Periodontitis
Not yet recruiting
Clinical and Inflammatory Outcomes of Regenerative Endodontic Treatment Using Injectable Platelet-Rich Fibrin in Mature Necrotic Teeth With Chronic Apical Periodontitis.
Chronic Apical Periodontitis, Pulp Necrosis
Recruiting
Effect of Cyperus Articulatus on Bacterial Reduction and Postoperative Pain
Chronic Apical Periodontitis
RecruitingObservational study
Prevalence and Associated Factors of High BMI and Periodontitis in Thai Adults Aged Under 60 Years
Diabete Mellitus, Dyslipidaemia
RecruitingObservational study
Evaluation of Masticatory Performance in Patients With Periodontitis
Periodontitis, Adult, Periodontitis
Recruiting
Postoperative Pain and Success of Single-Visit Root Canal Treatment Using Different Root Canal Sealers in Asymptomatic Teeth
Single-visit, Periapical Periodontitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Periodontitis and Chronic Periodontitis Wth Diabetes Mellitus, run by Amar h Zireg at 1 site in Algeria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Algeria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Visible reduction in gingival inflammation and erythema (redness) observed within 7 to 14 days (time frame: 7 to 14 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Apr 2026.